Table 1.
Impact of HPV on outcome in head and neck cancer
| Study | Patients tested | Therapeutic regimens | HPV+/tested (%HPV+) | Result- survival (%) | HPV+/HPV− |
|---|---|---|---|---|---|
| RTOG 01-29 [1] | 323/433 (75 %) | CRT versus RT | 206/323 (65) | 2-year OS | 88 versus 66 |
| 2-year PFS | 72 versus 50 | ||||
| HeadStart, international [2] | 195/465 (42 %) | CRT versus CRT | 54/195 (28) | 2-year OS | 94 versus 77 |
| 2-year PFS | NA | ||||
| TAX 324 [3] | 111/264 (42 %) | ST versus ST | 56/111 (50) | 5-year OS | 82 versus 35 |
| 5-year PFS | 78 versus 28 |
OS overall survival; PFS progression-free survival; HPV human papillomavirus; RTOG Radiation Therapy Oncology Group; CRT chemoradiotherapy; RT radiotherapy; ST sequential therapy; NA not available